Regulatory acceleration Target clinical research sponsors and CROs that require rapid Institutional Biosafety Committee (IBC) reviews for gene therapy trials. Clinical Biosafety Services positions itself as an accelerator of approvals, offering compliant, expedited review to shorten trial timelines.

Specialized expertise Highlight the niche focus on gene transfer and gene therapy trials with site-specific IBC reviews. Leverage this specialization to pursue biotech firms developing novel therapies needing experienced biosafety consulting to navigate regulatory hurdles.

Sizable partner network Leverage Sabai Global backing and potential cross-sell opportunities with sister entities in biotech and regulatory services. Position as a trusted partner capable of handling both institutional and sponsor needs in biosafety reviews.

Mid-market growth With a revenue range of several million dollars and a lean team, pursue mid-market biotech, academic medical centers, and small to mid-sized biopharma companies expanding gene therapy pipelines that require scalable biosafety support without large-scale vendor overhead.

Technology-enabled operations Promote the use of established tech stack and modern tools to deliver efficient, auditable IBC review processes. Emphasize potential for внедрения process automation and data insights to further accelerate review cycles for clients.